Paradigm Biopharmaceuticals Ltd's (ASX:PAR) chief operating officer Dr Jeannie Joughin discusses with Proactive's Andrew Scott a new agreement with bene pharmaChem which allows for the further development of injectable Pentosan Polysulfate Sodium (iPPS) and other formulations containing PPS to address unmet needs in new clinical indications. Dr Joughin also updates on their planned pivotal study in subjects with pain associated with Knee Osteoarthritis following its submission of an Investigational New Drug application to the US Food and Drug Administration.
Paradigm Biopharma talks new deal with bene pharmaChem and upcoming phase 3 osteoarthritis program
